Key Findings
The North America beta glucan market is expected to progress at a 7.50% CAGR during the forecast period of 2019-2027. The unexploited beta glucan applications in cosmetic and medicine sector are expected to present this market with potential growth opportunities.

Market Insights
The North American Beta glucan market is driven by increasing funding done by the private and rising prevalence of diseases such as cancer and diabetes which is increasing rapidly thereby boosting the demand for beta glucan market in the coming years. The pharmaceutical industry is an important end-user in the North American beta-glucan market. Other key end-users in this market include animal feed, personal care, and food and beverages industry. In 2018, the US market accounted for the highest share in the North America beta-glucan market. It was followed by the Canadian beta-glucan market, which is expected to progress at a CAGR of xx%. The country’s growing diabetic population and increasing number of ongoing clinical trials are boosting its market growth.

Competitive Insights
Ceapro Inc., Immunomedic AS, Lesaffre Human Care, Tate and Kyle PLC, DSM NV, Kerry Group PLC, Biotech PharmaCon ASA, Millipore Sigma, Cargill Incorporated, Super Beta Glucan Inc., Garuda International Inc., and Kemin Industries are few of the established market companies in this region.